Diclofenac reduces the risk of Alzheimer's disease: a pilot analysis of NSAIDs in two US veteran populations.

Olaf StüveRick A WeidemanDanni M McMahanDavid A JacobBertis B Little

Published in: Therapeutic advances in neurological disorders (2020)

Diclofenac, which has been shown to have active transport into the central nervous system, and which has been shown to lower amyloid beta and interleukin 1 beta, is associated with a significantly lower frequency of AD compared with etodolac and naproxen. These results are compelling, and parallel animal studies of the closely related fenamate NSAID drug class.

Keyphrases

cognitive decline
cerebrospinal fluid
study protocol
case control
adverse drug
genetic diversity
mild cognitive impairment